Skip to content
rolofylline

Structure via PubChem · Public domain (PubChem)

EntityQ7361410· pop 8· linked from 189 articles

rolofylline

Sign in to save

Also known as KW-3902, NAX

Rolofylline (KW-3902) is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist. It was discovered at NovaCardia, Inc. which was purchased by Merck & Co., Inc. in 2007.

Chemical data

Formula
C20H28N4O2
Molecular weight
356.5 g/mol
IUPAC name
1,3-dipropyl-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 3
Molecule type
Small molecule
Indications
heart failure, congestive heart failure

via ChEMBL · EBI

~1 min read

Encyclopedic overview

1 sections
Contents
  • References

Rolofylline (KW-3902) is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist. It was discovered at NovaCardia, Inc. which was purchased by Merck & Co., Inc. in 2007.

Development of rolofylline was terminated on September 1, 2009, after the results of a large clinical trial (PROTECT) showed the drug to be no better than placebo for patients with acute heart failure. Participants given rolofylline did show some improvement in shortness of breath, but the drug did not prevent kidney damage or have any significant effect on overall treatment success. Rolofylline was also associated with a higher incidence of seizures and stroke.

Excerpted from Wikipedia’s “rolofylline” article, available under the CC BY-SA 4.0 licence.

Available in 8 languages

via Wikidata sitelinks · CC0